Published in
Wiley, British Journal of Haematology, 3(202), p. 498-503, 2023
DOI: 10.1111/bjh.18894
Links
Tools
Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes
,
Vinit Upasani,
Charlotte Gaskell,
Sonia Fox,
Rachel Fletcher,
Catherine Thomas,
Louise Hopkins,
Anita Kumari,
Tina Tang,
Emily Yafai,
Rebecca Boucher,
Victoria Homer,
Arpad Toth,
Y. L. Tracey Chan,
Katie Randall
and other authors.
Full text: Unavailable
Abstract
SummaryLimited data exist on COVID‐19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS‐EB2). We report results from a prospective study, PACE (Patients with AML and COVID‐19 Epidemiology). 93 patients provided samples post‐vaccine 2 or 3 (PV2, PV3). Antibodies against SARS‐COV‐2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T‐cell reactivity to SARS‐COV‐2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.